Novartis: phase 2 data reinforce efficacy of migraine drug

(CercleFinance.com) - Novartis on Monday unveiled phase 2 results reinforcing the long-term safety and efficacy of migraine drug Aimovig in patients with episodic migraine.


The results of the five-year study - which enrolled 383 patients - showed Aimovig helped patients achieve sustained reductions in monthly migraine days (MMD) and in use of acute migraine-specific medication (AMSM), the Swiss drugmaker said.

Among the 216 patients who completed the treatment phase, there was an average MMD reduction of 5.3 days from a baseline of 8.7 days.

By the end of the study, patients who used AMSM to treat their migraine headaches experienced an average reduction in AMSM use of 4.4 days from a baseline of 6.2 days.

The results were presented at the Migraine Trust Virtual Symposium.

For the record, Aimovig is being co-marketed in the US by Amgen and Novartis.

Copyright (c) 2020 CercleFinance.com. All rights reserved.